What causes elevated serum prealbumin and glycocholic acid levels?
Serum prealbumin (also known as transthyretin) and serum glycochenodeoxycholic acid (GCDCA)—often referred to colloquially as “glycocholic acid” or “glycocholate”—are distinct biomarkers with different physiological roles and clinical implications. It is important to clarify that elevated levels of these two markers rarely occur together for the same underlying reason, and their simultaneous elevation warrants careful, differential interpretation.
Prealbumin is a hepatic-synthesized transport protein with a short half-life (~2 days), making it a sensitive early indicator of hepatic synthetic dysfunction or acute malnutrition. A *low* prealbumin level is commonly associated with liver disease (e.g., cirrhosis, acute hepatitis), severe malnutrition, chronic inflammation, or critical illness. Conversely, *elevated* prealbumin is uncommon and not routinely clinically significant; when observed, it may reflect transient states such as corticosteroid use, hyperthyroidism, or recovery from acute illness—but it is not considered a primary diagnostic marker for pathology.
In contrast, glycochenodeoxycholic acid (GCDCA) is a conjugated secondary bile acid formed in the gut by bacterial dehydroxylation of chenodeoxycholic acid and subsequently reabsorbed via the enterohepatic circulation. Serum GCDCA rises significantly in conditions involving impaired hepatic uptake, intrahepatic or extrahepatic cholestasis, or reduced bile acid clearance—such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), drug-induced cholestasis, or obstructive jaundice due to choledocholithiasis or malignancy. Elevated GCDCA is a highly specific marker of cholestatic liver injury and often precedes increases in conventional liver enzymes (e.g., ALP, GGT) or bilirubin.
Therefore, if both prealbumin and GCDCA are reported as “high” in the same clinical context, the finding should prompt verification: prealbumin elevation is atypical and may reflect assay interference, laboratory error, or a non-hepatic confounder (e.g., recent steroid administration). Clinically, the priority is to investigate the cause of elevated GCDCA—through liver ultrasound, MRCP or ERCP if indicated, serologic testing (e.g., AMA, ANCA), and assessment of other cholestasis markers. A comprehensive evaluation including history, physical exam, and additional liver function tests is essential to determine whether the abnormality reflects hepatocellular injury, cholestasis, metabolic disorder, or an extrahepatic process.